Difference between revisions of "Epoetin alfa-epbx (Retacrit)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors. A biosimilar of epoetin. For...") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
(5 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors. A biosimilar of epoetin. | Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors. A biosimilar of epoetin. | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | * | + | * 2018-05-15: FDA approved "for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis, use of zidovudine in patients with HIV infection, and the effects of concomitant myelosuppressive chemotherapy. It is also approved for the reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery." |
==Also known as== | ==Also known as== | ||
Line 13: | Line 13: | ||
<references/> | <references/> | ||
− | [[Category: | + | [[Category:Drugs]] |
+ | [[Category:Intravenous medications]] | ||
+ | [[Category:Subcutaneous medications]] | ||
+ | |||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Erythrocyte growth factors]] | [[Category:Erythrocyte growth factors]] | ||
− | [[Category: | + | [[Category:FDA approved in 2018]] |
[[Category:Biosimilars]] | [[Category:Biosimilars]] |
Latest revision as of 01:00, 29 June 2024
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors. A biosimilar of epoetin.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
History of changes in FDA indication
- 2018-05-15: FDA approved "for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis, use of zidovudine in patients with HIV infection, and the effects of concomitant myelosuppressive chemotherapy. It is also approved for the reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery."
Also known as
- Brand name: Retacrit